ASCO 2020 annual meeting

Programme du congrès
Lieu : Chicago, Illinois
Pays : Etats-Unis
Langue : ENG
Date de début :
Date de fin :
Spécialités : Oncologie
Cancer du sein : identification de biomarqueurs potentiels pour prédire lefficacité du ribociclib

- Date : 29/05/2020
- 6
0
Brian Jonas, ASCO20: Venetoclax combination treatment in older patients with acute myeloid leukemia

- Date : 29/05/2020
- 3
0
PART 1: Yuval Shaked, ASCO 2020: Host Response Profiling for Melanoma Patients

- Date : 29/05/2020
- 1
0
John Kuruvilla, ASCO20: Results of the KEYNOTE-204 Phase III Trial in Patients with cHL

- Date : 29/05/2020
- 1
0
PART 2: Yuval Shaked, ASCO 2020: Host Response Profiling for Melanoma Patients

- Date : 29/05/2020
- 1
0
ASCO Global Webinar Series: April 21, Laboratory Research & Screening Patients

- Date : 02/06/2020
- 1
0
MINDACT long-term results: 70-gene signature MammaPrint to guide adjuvant chemotherapy use

- Date : 29/05/2020
- 1
0
PANDA: Combining panitumumab with FOLFOX or 5FU in elderly patients with RAS-BRAF WT

- Date : 29/05/2020
- 1
0
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients

- Date : 29/05/2020
- 1
0
Cisplatin +/- veliparib in metastatic TNBC and/or germline BRCA-associated breast cancer

- Date : 29/05/2020
- 1
0
Le programme CAPRI démontre l'efficacité du suivi à distance des traitements oraux

- Date : 29/05/2020
- 0
0
Résultats prometteurs d'une association de thérapies ciblées dans le gliome de l'enfant

- Date : 29/05/2020
- 0
0
ASCO Global Webinar Series July 28, Experiences and Lessons During the COVID-19 Pandemic

- Date : 28/06/2020
- 0
0
ASCO Global Webinar Series: June 30, Learning Through Collaboration -- Population-Based Research

- Date : 30/06/2020
- 0
0
ASCO Global Webinar Series: April 14, Experiences and Lessons During the COVID 19 Pandemic

- Date : 14/04/2020
- 0
0
ASCO Global Webinar Series: May 12, Practice Plans for Transitioning Back to Standard Operations

- Date : 12/04/2020
- 0
0
Perioperative novel systemic immunotherapy-based approaches in urinary cancers

- Date : 29/05/2020
- 0
0
COMBI-AD trial: Adjuvant dabrafenib plus trametinib in patients with resected stage III BRAF

- Date : 29/05/2020
- 0
0
IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial cancer

- Date : 29/05/2020
- 0
0
FGFR inhibitors in bladder cancer: Testing, screening and highlights from ASCO 2020

- Date : 29/05/2020
- 0
0
High-dose twice daily thoracic radiotherapy in limited disease small-cell lung cancer

- Date : 29/05/2020
- 0
0
ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for patients

- Date : 29/05/2020
- 0
0
Reducing damage to swallowing muscles during radiotherapy for head and neck cancers

- Date : 29/05/2020
- 0
0
HCRN GU16-260: Nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients

- Date : 29/05/2020
- 0
0
PARP inhibitors in prostate cancer: Guidelines, who to test and the patient pathway

- Date : 29/05/2020
- 0
0
Early safety from a trial of talimogene laherparepvec (T-VEC) injected into liver tumours

- Date : 29/05/2020
- 0
0
3-weekly cisplatin or weekly cisplatin for squamous cell carcinoma of head and neck

- Date : 29/05/2020
- 0
0
US MM-6: Long-term proteasome inhibition in multiple myeloma following an in-class transition

- Date : 29/05/2020
- 0
0
Three versus six months of adjuvant oxaliplatin and fluoropyrimidine-based therapy for patients

- Date : 29/05/2020
- 0
0
Osimertinib plus gefitinib for treatment of EGFR-mutated non-small cell lung cancer

- Date : 29/05/2020
- 0
0
Comparing pevonedistat plus azacitidine versus azacitidine alone in patients with higher-risk

- Date : 29/05/2020
- 0
0
FORTE trial: Minimal residual disease evaluation in newly diagnosed multiple myeloma

- Date : 29/05/2020
- 0
0
Perioperative chemotherapy with mfolfirinox vs gemcitabine/nab-paclitaxel for resectable

- Date : 29/05/2020
- 0
0
CTC count as a prognostic marker for androgen deprivation plus orteronel or bicalutamide in mCSPC

- Date : 29/05/2020
- 0
0
TROPHIMMUN: Avelumab for gestational trophoblastic tumours resistant to monochemotherapy

- Date : 29/05/2020
- 0
0
KEYNOTE-177 results: Pembrolizumab versus chemotherapy for patients with MSI-H/dMMR colorectal

- Date : 29/05/2020
- 0
0
Timing of response to venetoclax combination treatment in older patients with acute myeloid

- Date : 29/05/2020
- 0
0
Venetoclax with bortezomib and dexamethasone in relapsed/refractory multiple myeloma

- Date : 29/05/2020
- 0
0
LuPSMA vs cabazitaxel in metastatic castration-resistant prostate cancer progressing

- Date : 29/05/2020
- 0
0
Cumulative incidence of financial hardship in metastatic colorectal cancer patients

- Date : 29/05/2020
- 0
0
Association of BRCA alternations with response to PARP inhibitors in metastatic

- Date : 29/05/2020
- 0
0
COM701 as a monotherapy and in combination with nivolumab for various advanced solid tumours

- Date : 29/05/2020
- 0
0
Teclistamab for patients with heavily pretreated relapsed or refractory multiple myeloma

- Date : 29/05/2020
- 0
0
E2108: Systemic therapy plus early local therapy versus systemic therapy alone

- Date : 29/05/2020
- 0
0
The paediatric precision oncology study INFORM: Clinical outcome and benefit for molecular

- Date : 29/05/2020
- 0
0
Maintenance avelumab plus best supportive care (BSC) versus BSC alone after chemotherapy

- Date : 29/05/2020
- 0
0
KEYNOTE-604: Pembrolizumab plus etoposide and platinum as a first-line therapy

- Date : 29/05/2020
- 0
0
CARTITUDE-1: JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy

- Date : 29/05/2020
- 0
0
ASCO 2020: Pembrolizumab plus chemotherapy for patients with metastatic triple-negative

- Date : 29/05/2020
- 0
0
CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory multiple myeloma

- Date : 29/05/2020
- 0
0
AGMT_MM-1: Investigating the oral microbiome in patients with relapsed/refractory multiple myeloma

- Date : 29/05/2020
- 0
0
Pembrolizumab vs brentuximab vedotin in relapsed or refractory classic Hodkin lymphomavvvv

- Date : 29/05/2020
- 0
0
KEYNOTE-427 updates: First-line pembrolizumab monotherapy in patients with advanced clear

- Date : 29/05/2020
- 0
0
Association of gene expression with clinical outcomes in advanced RCC patients treated

- Date : 29/05/2020
- 0
0
FRACTION-RCC: Evaluating nivolumab plus ipilimumab in patients with treatment-refractory

- Date : 29/05/2020
- 0
0